ECM
GLUE icon

ExodusPoint Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

ExodusPoint Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100,000
Closed -$630K – 1659
2023
Q4 		$630K Buy
+100,000
New +$392K ﹤0.01% 972

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

ExodusPoint Capital Management's GLUE Position: Q3 2025 in Review

ExodusPoint Capital Management sold out of Monte Rosa Therapeutics (GLUE) in Q3 2025, closing a stake of 109,227 shares — an estimated $493K sold.

ExodusPoint Capital Management first reported a position in GLUE in Q1 2023 and held it in 9 quarters. The position peaked at $4.59M in Q2 2023. 129 funds tracked by Wall St. Rank hold GLUE as of Q3 2025.

  • ExodusPoint Capital Management reported no remaining Monte Rosa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 109,227 Monte Rosa Therapeutics shares in Q3 2025, an estimated $493K.
  • ExodusPoint Capital Management first reported a position in Monte Rosa Therapeutics in Q1 2023 and held it in 9 quarters.
  • ExodusPoint Capital Management's Monte Rosa Therapeutics position peaked at $4.59M in Q2 2023.
  • 129 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.